Biogen Shares Fall as Alzheimer's Drug Data Reveals Puzzling Dose Response

Biogen Inc. (NASDAQ: BIIB) shares tumbled on Tuesday after the company released perplexing Phase 2 trial data for its experimental Alzheimer’s therapy, diranersen. The stock fell by as much as 8.7% as investors weighed a major scientific achievement in clearing a key protein against the trial's failure to meet its primary clinical goal due to an unusual dosing paradox.

A Paradoxical Outcome

The Phase 2 CELIA study missed its primary endpoint of demonstrating a dose-dependent effect on slowing cognitive decline, as measured by the CDR-SB scale. Instead, the results showed an inverse response, where the lowest dose proved most effective, leaving analysts and investors questioning the drug's path forward.

Key clinical efficacy findings from the trial include:

• 60 mg dose: Slowed cognitive decline by 26%.
• 115 mg dose (every 6 months): Slowed decline by 14%.
• 115 mg dose (every 3 months): Slowed decline by just 9%.

Furthermore, the higher-dose arms were associated with significant tolerability issues, leading to discontinuation rates of 20% to 25%, driven by severe procedure-related pain and confusional states, according to the source report.

Scientific Milestone Clouded by Questions

Ad

Despite the clinical setback, diranersen achieved a significant biomarker milestone. The therapy demonstrated a robust 50% to 65% reduction in total tau in cerebrospinal fluid (CSF)—the first treatment to show such a strong effect on the protein pathology central to Alzheimer's disease.

Crucially, diranersen also showed a superior safety profile, with 0% incidence of amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding. This stands in stark contrast to existing anti-amyloid treatments, where ARIA rates in real-world use are around 10%, potentially giving diranersen a significant safety advantage.

Wall Street Divided on Path Forward

Analysts expressed mixed reactions to the data. Morgan Stanley noted that the efficacy of the best-performing dose was at the low end of expectations and that management's inability to explain the inverse dose response was a key driver of the stock's decline.

In contrast, Jefferies took a more optimistic view, highlighting that the 26% slowing of decline is in line with the benchmark set by approved anti-amyloid therapies. Some analysts theorized a potential "ceiling effect" for tau reduction, while others believe the data validates the drug's mechanism of targeting intracellular tau. Biogen plans to advance diranersen to a Phase 3 trial, but now faces pressure to resolve the dosing mystery to design a successful study.